丹麦心血管筛查(DANCAVAS)试验的五年结局
DANCAVAS是一项基于人群的平行组随机对照试验,纳入丹麦15个市镇65至74岁男性,按1:2随机分为受邀筛查组(16736人)和对照组(29790人)。筛查包括非对比心电图门控CT测冠状动脉钙化积分并检出动脉瘤和房颤、踝臂血压测外周动脉疾病和高血压、血样测糖尿病和高胆固醇血症。中位随访5.6年,意向性分析显示受邀组全因死亡12.6% vs 对照组13.1%(HR 0.95,95%CI 0.90–1.00,P=0.06),未达统计学显著。卒中HR 0.93(95%CI 0.86–0.99),心肌梗死HR 0.91(95%CI 0.81–1.03),主动脉夹层HR 0.95(95%CI 0.61–1.49),主动脉破裂HR 0.81(95%CI 0.49–1.35),安全结局组间无显著差异。
要点
- 受邀筛查组全因死亡12.6%(2106/16736)vs 对照组13.1%(3915/29790),HR 0.95(95%CI 0.90–1.00),P=0.06,未达统计学显著。
- 受邀组卒中风险低于对照组:HR 0.93(95%CI 0.86–0.99)。
- 心肌梗死HR 0.91(95%CI 0.81–1.03)、主动脉夹层HR 0.95(95%CI 0.61–1.49)、主动脉破裂HR 0.81(95%CI 0.49–1.35),均未达统计学显著。
- 受邀组16736人中10471人(62.6%)实际接受筛查。
- 安全结局组间无显著差异。
适用人群与场景
- 居住在丹麦15个市镇的65至74岁男性。
- 随机分组前已死亡或移民的85名男性被排除。
诊断标准与关键阈值
- 筛查项目包括:非对比心电图门控计算机断层扫描(测定冠状动脉钙化积分、检出动脉瘤和心房颤动)、踝臂血压测量(检出外周动脉疾病和高血压)、血样检测(检出糖尿病和高胆固醇血症)。
研究设计与关键结果
- 研究类型:基于人群的平行组随机对照试验;随机化按市镇分层,采用计算机生成的随机数字,按1:2比例分为受邀筛查组和对照组,仅对照组对分组设盲。
- 样本量:共46611人接受随机化;排除85名在受邀筛查前死亡或移民的男性后,受邀组16736人、对照组29790人;受邀组中10471人(62.6%)实际接受筛查。
- 主要终点:中位随访5.6年后,受邀组死亡2106人(12.6%),对照组死亡3915人(13.1%),风险比(HR)0.95(95%置信区间[CI] 0.90至1.00;P=0.06)。
- 关键次要终点:卒中HR 0.93(95%CI 0.86至0.99);心肌梗死HR 0.91(95%CI 0.81至1.03);主动脉夹层HR 0.95(95%CI 0.61至1.49);主动脉破裂HR 0.81(95%CI 0.49至1.35)。
- 安全性结局:组间无显著差异。
证据类型、等级与局限
- 证据类型:随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对65至74岁男性,受邀参加综合心血管筛查未显著降低全因死亡(HR 0.95,P=0.06),不能据此认为筛查可降低该人群全因死亡;卒中风险轻度降低(HR 0.93)。
指南或共识出处
- DANCAVAS ISRCTN注册号:ISRCTN12157806;由丹麦南部地区等资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Limited data suggest a benefit of population-based screening for cardiovascular disease with respect to the risk of death.
METHODS: We performed a population-based, parallel-group, randomized, controlled trial involving men 65 to 74 years of age living in 15 Danish municipalities. The participants were randomly assigned in a 1:2 ratio to undergo screening (the invited group) or not to undergo screening (the control group) for subclinical cardiovascular disease. Randomization was based on computer-generated random numbers and stratified according to municipality. Only the control group was unaware of the trial-group assignments. Screening included noncontrast electrocardiography-gated computed tomography to determine the coronary-artery calcium score and to detect aneurysms and atrial fibrillation, ankle-brachial blood-pressure measurements to detect peripheral artery disease and hypertension, and a blood sample to detect diabetes mellitus and hypercholesterolemia. The primary outcome was death from any cause.
RESULTS: A total of 46,611 participants underwent randomization. After exclusion of 85 men who had died or emigrated before being invited to undergo screening, there were 16,736 men in the invited group and 29,790 men in the control group; 10,471 of the men in the invited group underwent screening (62.6%). In intention-to-treat analyses, after a median follow-up of 5.6 years, 2106 men (12.6%) in the invited group and 3915 men (13.1%) in the control group had died (hazard ratio, 0.95; 95% confidence interval [CI], 0.90 to 1.00; P = 0.06). The hazard ratio for stroke in the invited group, as compared with the control group, was 0.93 (95% CI, 0.86 to 0.99); for myocardial infarction, 0.91 (95% CI, 0.81 to 1.03); for aortic dissection, 0.95 (95% CI, 0.61 to 1.49); and for aortic rupture, 0.81 (95% CI, 0.49 to 1.35). There were no significant between-group differences in safety outcomes.
CONCLUSIONS: After more than 5 years, the invitation to undergo comprehensive cardiovascular screening did not significantly reduce the incidence of death from any cause among men 65 to 74 years of age. (Funded by the Southern Region of Denmark and others; DANCAVAS ISRCTN Registry number, ISRCTN12157806.).
参考来源
- Lindholt JS, Søgaard R, Rasmussen LM, et al. Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial. N Engl J Med. 2022. PMID: 36027560. doi:10.1056/NEJMoa2208681
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。